Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Bought by Smartleaf Asset Management LLC

Smartleaf Asset Management LLC lifted its position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 95.6% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 442 shares of the biotechnology company’s stock after acquiring an additional 216 shares during the quarter. Smartleaf Asset Management LLC’s holdings in Sarepta Therapeutics were worth $54,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in SRPT. Simplify Asset Management Inc. boosted its position in Sarepta Therapeutics by 84.6% during the 3rd quarter. Simplify Asset Management Inc. now owns 193,010 shares of the biotechnology company’s stock valued at $24,105,000 after purchasing an additional 88,474 shares during the period. Geode Capital Management LLC boosted its position in Sarepta Therapeutics by 2.7% during the 3rd quarter. Geode Capital Management LLC now owns 1,696,354 shares of the biotechnology company’s stock valued at $211,910,000 after purchasing an additional 44,306 shares during the period. Summit Partners Public Asset Management LLC boosted its position in Sarepta Therapeutics by 547.9% during the 3rd quarter. Summit Partners Public Asset Management LLC now owns 138,118 shares of the biotechnology company’s stock valued at $17,250,000 after purchasing an additional 116,800 shares during the period. Larson Financial Group LLC boosted its position in Sarepta Therapeutics by 1,649.8% during the 3rd quarter. Larson Financial Group LLC now owns 8,749 shares of the biotechnology company’s stock valued at $1,093,000 after purchasing an additional 8,249 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. boosted its position in Sarepta Therapeutics by 30.1% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 78,244 shares of the biotechnology company’s stock valued at $9,772,000 after purchasing an additional 18,095 shares during the period. Institutional investors and hedge funds own 86.68% of the company’s stock.

Analyst Ratings Changes

SRPT has been the subject of a number of analyst reports. HC Wainwright restated a “sell” rating and set a $75.00 price objective on shares of Sarepta Therapeutics in a research report on Thursday, February 27th. Needham & Company LLC restated a “buy” rating and set a $202.00 price objective on shares of Sarepta Therapeutics in a research report on Thursday, February 27th. Scotiabank assumed coverage on Sarepta Therapeutics in a research note on Friday. They set a “sector perform” rating and a $105.00 target price on the stock. Royal Bank of Canada reduced their price target on Sarepta Therapeutics from $165.00 to $161.00 and set an “outperform” rating for the company in a research report on Thursday, February 27th. Finally, StockNews.com lowered Sarepta Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, November 20th. One analyst has rated the stock with a sell rating, four have assigned a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $170.41.

Sarepta Therapeutics Price Performance

Shares of SRPT opened at $99.69 on Tuesday. The company has a market capitalization of $9.67 billion, a price-to-earnings ratio of 79.75 and a beta of 0.79. Sarepta Therapeutics, Inc. has a fifty-two week low of $98.82 and a fifty-two week high of $173.25. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03. The business’s 50-day moving average is $113.68 and its 200-day moving average is $120.98.

Insider Activity

In other news, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the company’s stock in a transaction dated Thursday, December 12th. The stock was sold at an average price of $124.84, for a total value of $1,310,820.00. Following the transaction, the director now owns 22,840 shares in the company, valued at $2,851,345.60. This represents a 31.49 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 7.70% of the stock is owned by corporate insiders.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.